Companies: 10,795·Total market cap: $144.5T
Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc.

PCSANASDAQHealthcare● Active
$2.42
$-0.10(-3.97%)
Market Cap$5483159
P/E Ratio
52W High$19.625
52W Low$1.76
Overview

Processa Pharmaceuticals, Inc. (PCSA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · PCSA · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-10.66pcsa eps ttm · pcsa earnings per shareEarnings history
PE Ratio (TTM)pcsa pe ratio ttm · pcsa price to earningsPE Ratio deep dive
Revenue (TTM)0.00pcsa revenue ttm · pcsa annual revenueFull revenue history
Dividend YieldNo Dividenddoes pcsa pay dividends · pcsa dividend yieldDividend history
Shares Outstanding1.3Mpcsa shares outstanding · pcsa floatShares outstanding history
Next EarningsAug 6, 2026Est.pcsa earnings date · pcsa next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
processa pharmaceuticals, inc. revenue · pcsa revenue 2025
FY 2025Net Income-$13.6M▼ 14.46% YoY
202320242025
processa pharmaceuticals, inc. net income · pcsa profit 2025
FY 2025EPS$-10.36▲ +89.29% YoY
202320242025
pcsa eps · processa pharmaceuticals, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$14.1MEPS: $-10.66View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis pcsa a buy · pcsa analyst rating
Strong Buy
0
Buy
4
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$225.00Low
$2.42Current
$225.00Avg Target9197.52% upside
$225.00High
pcsa price target · pcsa 12 month forecast

Total: 5 · Buy rate: 80.0%

The PCSA analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $225.00, representing +9197.52% upside from the current price of $2.42.

Stock Performance

Full History
1D-3.97%
1W-14.49%
1M-11.36%
3M-13.57%
YTD-15.97%
1Y-70.20%
5Y-99.93%

About Processa Pharmaceuticals, Inc.

CEOGeorge K. Ng
IPO DateMar 7, 2014
Employees10
CountryUS

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical re…

what is processa pharmaceuticals, inc. · pcsa stock overview · processa pharmaceuticals, inc. company profile · who is processa pharmaceuticals, inc. ceo · pcsa NASDAQ · processa pharmaceuticals, inc. headquarters · processa pharmaceuticals, inc. business segments

About Stock Overview & Key Data

Processa Pharmaceuticals, Inc. (PCSA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 7, 2014. As of the latest trading session, PCSA stock price is $2.42, with a market capitalization of $5.5M. The stock has returned -70.20% over the past 12 months and -15.97% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Processa Pharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $225.00. In fiscal year 2025, Processa Pharmaceuticals, Inc. reported revenue of — and net income of -$13.6M. For detailed data — including Processa Pharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Processa Pharmaceuticals, Inc. (PCSA) stock price is $2.42. The stock is traded on NASDAQ under the ticker symbol PCSA. The 52-week range is $1.76 – $19.63.

PCSA stock pricePCSA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice